Fosaprepitant

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fosaprepitant
Skeletal formula of fosaprepitant
Space-filling model of the fosaprepitant molecule
Clinical data
AHFS/Drugs.com Multum Consumer Information
MedlinePlus a604003
License data
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability n/a
Protein binding >95% (aprepitant)
Metabolism To aprepitant
Elimination half-life 9 to 13 hours (aprepitant)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C23H22F7N4O6P
Molar mass 614.406 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2]

See also[edit]

References[edit]

  1. ^ "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Retrieved 2008-03-15.
  2. ^ "European Public Assessment Report for Ivemend (from the EMEA website)". Archived from the original on 2008-02-28. Retrieved 2008-03-15.